Jong-Myon Bae1, Sung Ryul Shim2. 1. Department of Preventive Medicine, Jeju National University College of Medicine, Jeju, Republic of Korea. 2. Department of Preventive Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
Abstract
OBJECTIVE: Previous systematic reviews evaluating the association between coffee consumption and pancreatic cancer showed inconsistent results. The aim was to conduct a meta-epidemiological study to explore further the association between coffee consumption and the incidence of pancreatic cancer. METHODS: The selection criteria were defined as a population-based prospective cohort study reporting adjusted relative risk (RR) and their 95% confidence interval (95%CI) of pancreatic cancer occurrence according to coffee consumption. Adjusted RR for the highest versus the lowest level of coffee consumption in each study was extracted. A fixed-effect model was applied to calculate a summary RR (sRR) and its 95%CI. Two-stage random-effects dose-response meta-analysis (DRMA) was performed to estimate the incidence risk per unit dose (cup per day). RESULTS: Twelve cohort studies were selected for meta-analysis. The total number of cohort participants was 3,230,053, and pancreatic cancer incidents were 10,587. The sRR of pancreatic cancer risk for the highest versus the lowest level of coffee consumption indicated no statistical significance (sRR=0.98, 95% CI: 0.88-1.10; I-squared=0.0%). Two-stage random-effect DRMA showed the non-linear relationship between the amount of coffee consumption and pancreatic cancer risk. And the RR for an increment of one cup per day of coffee consumption was 0.97 (95%CI: 0.91-1.04, P=0.42), without statistically significant. CONCLUSION: There was no association between coffee consumption habits and pancreatic cancer risk. And there was no statistical significance in the dose-response relationship between the amount of coffee consumption and pancreatic cancer risk. Finding the turning point would be important because it can be critical information for the prevention of pancreatic cancer. <br />.
OBJECTIVE: Previous systematic reviews evaluating the association between coffee consumption and pancreatic cancer showed inconsistent results. The aim was to conduct a meta-epidemiological study to explore further the association between coffee consumption and the incidence of pancreatic cancer. METHODS: The selection criteria were defined as a population-based prospective cohort study reporting adjusted relative risk (RR) and their 95% confidence interval (95%CI) of pancreatic cancer occurrence according to coffee consumption. Adjusted RR for the highest versus the lowest level of coffee consumption in each study was extracted. A fixed-effect model was applied to calculate a summary RR (sRR) and its 95%CI. Two-stage random-effects dose-response meta-analysis (DRMA) was performed to estimate the incidence risk per unit dose (cup per day). RESULTS: Twelve cohort studies were selected for meta-analysis. The total number of cohort participants was 3,230,053, and pancreatic cancer incidents were 10,587. The sRR of pancreatic cancer risk for the highest versus the lowest level of coffee consumption indicated no statistical significance (sRR=0.98, 95% CI: 0.88-1.10; I-squared=0.0%). Two-stage random-effect DRMA showed the non-linear relationship between the amount of coffee consumption and pancreatic cancer risk. And the RR for an increment of one cup per day of coffee consumption was 0.97 (95%CI: 0.91-1.04, P=0.42), without statistically significant. CONCLUSION: There was no association between coffee consumption habits and pancreatic cancer risk. And there was no statistical significance in the dose-response relationship between the amount of coffee consumption and pancreatic cancer risk. Finding the turning point would be important because it can be critical information for the prevention of pancreatic cancer. <br />.
Authors: Bengt Isaksson; Fredrik Jonsson; Nancy L Pedersen; Jörgen Larsson; Maria Feychting; Johan Permert Journal: Int J Cancer Date: 2002-03-20 Impact factor: 7.396
Authors: L J Harnack; K E Anderson; W Zheng; A R Folsom; T A Sellers; L H Kushi Journal: Cancer Epidemiol Biomarkers Prev Date: 1997-12 Impact factor: 4.254
Authors: Lena Maria Nilsson; Ingegerd Johansson; Per Lenner; Bernt Lindahl; Bethany Van Guelpen Journal: Cancer Causes Control Date: 2010-05-30 Impact factor: 2.506
Authors: Charlie D Zhou; Ai Seon Kuan; Gillian K Reeves; Jane Green; Sarah Floud; Valerie Beral; TienYu Owen Yang Journal: Int J Cancer Date: 2018-12-28 Impact factor: 7.396
Authors: Nirmala Bhoo-Pathy; Cuno S P M Uiterwaal; Vincent K Dik; Suzanne M Jeurnink; Bodil H Bech; Kim Overvad; Jytte Halkjær; Anne Tjønneland; Marie-Christine Boutron-Ruault; Guy Fagherazzi; Antoine Racine; Verena A Katzke; Kuanrong Li; Heiner Boeing; Anna Floegel; Anna Androulidaki; Christina Bamia; Antonia Trichopoulou; Giovanna Masala; Salvatore Panico; Paolo Crosignani; Rosario Tumino; Paolo Vineis; Petra H M Peeters; Oxana Gavrilyuk; Guri Skeie; Elisabete Weiderpass; Eric J Duell; Marcial Arguelles; Esther Molina-Montes; Carmen Navarro; Eva Ardanaz; Miren Dorronsoro; Björn Lindkvist; Peter Wallström; Malin Sund; Weimin Ye; Kay-Tee Khaw; Nick Wareham; Timothy J Key; Ruth C Travis; Talita Duarte-Salles; Heinz Freisling; Idlir Licaj; Valentina Gallo; Dominique S Michaud; Elio Riboli; H Bas Bueno-De-Mesquita Journal: Clin Gastroenterol Hepatol Date: 2013-06-10 Impact factor: 11.382